Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

Application for AML Remission Maintenance Therapy

Advances on Schedule Following Meeting with EMEA

TARRYTOWN, N.Y., Sept. 18 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported that the assessment of its European Union centralized marketing authorization application for its lead oncology product Ceplene(TM) is advancing according to the anticipated regulatory timetable following a meeting yesterday. Ceplene (histamine dihydrochloride) has demonstrated important clinical benefit in the maintenance of remission for patients with Acute Myeloid Leukemia (AML).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

EpiCept's Marketing Authorization Application (MAA) for Ceplene has reached the next important step in its assessment by the Committee for Human Medicinal Products (CHMP). Specifically, EpiCept submitted full responses to the Day 120 Consolidated List of Questions. EpiCept's staff and expert consultants met on September 17 with EMEA officials and CHMP representatives to discuss these responses. Included with the Day 120 response documentation, EpiCept has provided data on Ceplene's effect on quality of life and on long term follow up of at least five years on leukemia-free survival for AML patients.

"We are pleased to have reached the latest regulatory milestone for Ceplene in the EU, and to be closer to our goal of providing hematologists with the first remission maintenance immunotherapy for AML patients," stated Jack Talley, President and Chief Executive Officer of EpiCept. "EpiCept outlined to the EMEA and CHMP representatives how the data package for Ceplene supports approval. We look forward to working with the regulators to complete their assessment. We are enthusiastic about the potential of Ceplene, which in our pivotal trial increased the long-term, disea
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... 14 Results of the PRoFESS(R),(Prevention Regimen For ... clinical research study for secondary stroke prevention --,were ... in Nice,France. In the study, recurrent stroke event ... 8.8%, respectively; HR 1.01, 95% CI,0.92-1.11). The study ...
... trial innovations advocate to lead expansion of Cytel,s ... adaptive trial design and implementation business, CAMBRIDGE, Mass., ... trial design services and specialized statistical software,today announced the ... Judith Quinlan brings over twenty years of statistical experience ...
Cached Medicine Technology:PRoFESS(R) Results Announced at XVII European Stroke Conference 2PRoFESS(R) Results Announced at XVII European Stroke Conference 3PRoFESS(R) Results Announced at XVII European Stroke Conference 4PRoFESS(R) Results Announced at XVII European Stroke Conference 5Judith Quinlan Joins Cytel as Vice President, Adaptive Trials 2
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... Calif. (PRWEB) August 30, 2014 Insomnia causes ... helps listeners understand how they unknowingly developed insomnia and the ... restful nights during. Tune in to the show at ... The show airs live on August 30, and will be ... information on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia ...
(Date:8/30/2014)... Grand Rapids, MI (PRWEB) August 30, 2014 ... Michigan residents, Forefront Dermatology is expanding with the addition ... Mich. Dr. David Hammond who has provided leading-edge skin ... practice with Forefront Dermatology. , “As a doctor, ... care they deserve. Through partnering with Forefront Dermatology, I’m ...
(Date:8/30/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... broken bones or other orthopedic trauma shops around for additional ... patients and patients who had used narcotic painkillers previously were ... lead author Dr. Brent Morris, a shoulder and neck surgeon ... doctors aren,t talking to one another about the painkiller needs ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... gloss, depth of image, and surface ... Texas, Oct. 22 Solvay Engineered Polymers,Inc., has ... in the,production of extruded sheet. The new ADDHERE(TM) ... layer onto a substrate of thermoplastic,polyolefin (TPO) for ...
... with Top Children,s Miracle Network Health Experts, SALT LAKE CITY, Oct. 22 /PRNewswire/, ... experts from 170 Children,s ... questions about Methicillin-resistant Staphylococcus Aureus ... to antibiotics, and other ...
... Chairman Howard Dean issued the following statement in response,to ... $46 billion,in war spending, for a total of $196 ... coverage to 10 million of America,s low income children:, ... to fund his war of,choice in Iraq but has ...
... There,s no proof cancer will spread to the ... (HealthDay News) -- Women diagnosed with breast cancer who ... other, healthy breast removed as a preventive measure. , ... mastectomy, more than doubled from 1998 to 2003, according ...
... 22 The start of the,patent lawsuit by VNUS(R) ... laser competitors, Diomed, AngioDynamics and Vascular,Solutions, has been delayed ... delay is due to a busy court calendar. A ... new trial start dates. At,the conference, the parties will ...
... 22 Dialysis Corporation,of America (Nasdaq: DCAI ... third,quarter 2007 earnings after the close of the ... of America owns and operates freestanding kidney,hemodialysis centers ... Carolina and Virginia, and provides in-hospital,dialysis services on ...
Cached Medicine News:Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4Health News:Children's Miracle Network Hospital Doctors On Call to Answer Questions About MRSA Infection 2Health News:More Women Choosing 'Preventive' Double Mastectomy 2Health News:More Women Choosing 'Preventive' Double Mastectomy 3Health News:Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion 2Health News:Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: